Norway’s Nykode Eyes NASDAQ As Pipeline Advances
Executive Summary
CEO Michael Engsig tells Scrip that his well-capitalized company has ambitious plans for US expansion and is looking to set up an autoimmune diseases arm to add to its oncology efforts.